These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 11400259)

  • 1. Cost prediction models for the comparison of two groups.
    Willan AR; O'Brien BJ
    Health Econ; 2001 Jun; 10(4):363-6. PubMed ID: 11400259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
    de Lissovoy G; Subedi P
    Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating mean hospital cost as a function of length of stay and patient characteristics.
    Polverejan E; Gardiner JC; Bradley CJ; Holmes-Rovner M; Rovner D
    Health Econ; 2003 Nov; 12(11):935-47. PubMed ID: 14601156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of Gram-negative resistance.
    Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
    Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials.
    Taira DA; Seto TB; Siegrist R; Cosgrove R; Berezin R; Cohen DJ
    Am Heart J; 2003 Mar; 145(3):452-8. PubMed ID: 12660668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.
    Nutescu EA; Steinmetz Pater K
    Expert Opin Pharmacother; 2008 Jan; 9(1):95-105. PubMed ID: 18076341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
    Sculpher MJ; Lozano-Ortega G; Sambrook J; Palmer S; Ormanidhi O; Bakhai A; Flather M; Steg PG; Mehta SR; Weintraub W
    Am Heart J; 2009 May; 157(5):845-52. PubMed ID: 19376310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparing individual costs for treatment in acute day and inpatient care--results from a randomised controlled trial].
    Kallert TW; Schönherr R; Fröhling D; Schützwohl M
    Psychiatr Prax; 2007 Nov; 34(8):377-83. PubMed ID: 17671918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proper modeling strategies selection for the assessment of post-infarction costs.
    Gregori D; Desideri A; Bigi R; Petrinco M; Cortigiani L; Zigon G; Pagano E
    Int J Cardiol; 2008 Sep; 129(1):53-8. PubMed ID: 17707925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 15. Hospital resources consumed for surgical morbidity: effects of preoperative arginine and omega-3 fatty acid supplementation on costs.
    Braga M; Gianotti L; Vignali A; Schmid A; Nespoli L; Di Carlo V
    Nutrition; 2005; 21(11-12):1078-86. PubMed ID: 16308130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising outcomes: socioeconomic perspective.
    Mark DB
    Heart; 1999 Sep; 82 Suppl 1(Suppl 1):I18-20. PubMed ID: 10469674
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).
    Zhao L; Zhang Z; Kolm P; Jasper S; Lewis C; Klein A; Weintraub W;
    Am J Cardiol; 2008 Feb; 101(3):338-42. PubMed ID: 18237596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
    Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
    Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis.
    Willan AR; Pinto EM; O'Brien BJ; Kaul P; Goeree R; Lynd L; Armstrong PW
    Health Econ; 2005 Apr; 14(4):327-38. PubMed ID: 15685652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.